<PAGE> 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 16, 1998
BIONUTRICS, INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-22011
NEVADA 86-0760991
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
2425 E. CAMELBACK RD., SUITE 650
PHOENIX, AZ 85016-4214
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 602-508-0112
<PAGE> 2
Item 7. Exhibit
PRESS RELEASE DATED FEBRUARY 26, 1998
<PAGE> 3
COMPANY CONTACT:
SANDRA GOTHAM MEEHAN
SENIOR VICE PRESIDENT
CORPORATE COMMUNICATIONS
BIONUTRICS, INC.
FOR IMMEDIATE RELEASE (212) 628-6810
INVESTOR RELATIONS CONTACT:
DONNA N. STEIN/DAN DURKIN/CINDY REID
MORGEN-WALKE ASSOCIATES, INC.
(212) 850-5600
PRESS CONTACT:
RICHARD DUKAS/ANN TRAVERS
MORGEN-WALKE ASSOCIATES, INC.
(212) 850-5600
BIONUTRICS, INC. SIGNS AGREEMENT WITH NOVARTIS NUTRITION
Phoenix, AZ, February 26, 1998 -- Bionutrics, Inc. (Nasdaq: BNRX) today
announced that it has signed an agreement with Novartis Nutrition, a subsidiary
of Novartis AG, a world leader in life sciences.
Under the agreement, Novartis Nutrition has made an initial investment in
Bionutrics by purchasing $3 million of Bionutrics' stock and has been granted
exclusive worldwide rights to evaluate Bionutrics' patented technology and rice
bran-derived products for potential application as functional food ingredients.
Novartis Nutrition is a division of Novartis AG, a world leader in life
sciences with core businesses in healthcare, agribusiness and nutrition. In
1997, Novartis Group sales were 31.2 billion Swiss francs (US$ 21.6 billion),
of which 18.8 billion (US$ 13.0 billion) were in healthcare, 8.3 billion (US$
5.8 billion) in agribusiness and 4.1 billion (US$ 2.8 billion) in nutrition.
The company annually invests more than 3 billion Swiss francs (US$ 2.1 billion)
in R&D. Headquartered in Basel, Switzerland, Novartis employs about 87,000
people and operates in over 100 countries.
Bionutrics is an emerging biopharmaceutical company founded to discover and
develop novel, biologically active compounds derived from natural sources.
Natural, biologically active compounds have applications as ethical drugs as
well as functional food ingredients and dietary supplements. Bionutrics intends
to develop and market products that target these three applications, and also
to generate profit by marketing the commodities that result from its processing
of natural products. The first compounds discovered and patented by Bionutrics
are novel tocotrienols from rice bran and are currently marketed as an
ingredient for dietary supplements called Clearesterol(TM). The first brand
that has been introduced is evolvE(R), Advanced Cardiovascular Dietary
Supplement, with cholesterol-lowering, anti-oxidation and healthy blood
circulation properties. evolvE(R) is available in over 40,000 stores
nationwide, representing every major drugstore chain and all major mass
merchandisers as well as GNC health stores.
EXHIBIT
3
<PAGE> 4
BIONUTRICS, INC.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Bionutrics, Inc.
(Registrant)
Dated: February 27, 1998 By: /s/ George E. Duck, Jr.
-------------------------
Its: Vice President, Finance
-------------------------
Secretary and Treasurer
-------------------------
4
